Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-689,560
说明： Highly potent NMDA antagonist
化学名： trans-2-Carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline
纯度： ≥99% (HPLC)
生物活性 for L-689,560
L-689,560 is a very potent antagonist at the glycine-NMDA site.
许可信息
Sold with the permission of Merck Sharp and Dohme Ltd.
化合物库 for L-689,560
L-689,560 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for L-689,560
| 分子量 | 380.23 |
| 公式 | C17H15Cl2N3O3 |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 139051-78-8 |
| PubChem ID | 6604749 |
| InChI Key | UCKHICKHGAOGAP-UONOGXRCSA-N |
| Smiles | ClC1=C2C(N[C@@H]([C@](O)=O)C[C@@H]2NC(NC3=CC=CC=C3)=O)=CC(Cl)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for L-689,560
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 9.51 | 25 | |
| ethanol | 38.02 | 100 |
制备储备液 for L-689,560
以下数据基于产品分子量 380.23。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.63 mL | 13.15 mL | 26.3 mL |
| 5 mM | 0.53 mL | 2.63 mL | 5.26 mL |
| 10 mM | 0.26 mL | 1.31 mL | 2.63 mL |
| 50 mM | 0.05 mL | 0.26 mL | 0.53 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for L-689,560
参考文献 for L-689,560
参考文献是支持产品生物活性的出版物。
Leeson et al (1992) 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationship for antagonism at the glycine site of the NMDA receptor. J.Med.Chem. 35 1954 PMID: 1534584
Stone (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. TiPS 21 149 PMID: 10740291
Leeson et al (1991) trans-2-Carboxy-4-substituted tetrahydroquinolines. Potent glycine-site NMDA receptor antagonists. Med.Chem.Res. 1 64
If you know of a relevant reference for L-689,560, please let us know.
按产品操作查看相关产品
关键词: L-689,560, L-689,560 supplier, potent, NMDA, antagonists, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, L689560, merck, 0742, Tocris Bioscience
9 篇 L-689,560 的引用文献
引用文献是使用了 Tocris 产品的出版物。 L-689,560 的部分引用包括：
Fang et al (2015) Regulated internalization of NMDA receptors drives PKD1-mediated suppression of the activity of residual cell-surface NMDA receptors. Toxicol Lett 8 75 PMID: 26584860
Ng et al (2014) Rapid regulation of endoplasmic reticulum dynamics in dendritic spines by NMDA receptor activation. Mol Brain 7 60 PMID: 25242397
Wall et al (2018) The Temporal Dynamics of Arc Expression Regulate Cognitive Flexibility. Neuron 98 1124 PMID: 29861284
Dennis et al (2016) Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus. Mol Brain 26 414 PMID: 26472558
Park et al (2016) Calcium-Permeable AMPA Receptors Mediate the Induction of the Protein Kinase A-Dependent Component of Long-Term Potentiation in the Hippocampus. J Neurosci 36 622 PMID: 26758849
Eales et al (2014) The MK2/3 cascade regulates AMPAR trafficking and cognitive flexibility. Nat Commun 5 4701 PMID: 25134715
Rouaud and Billard (2003) D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices. Br J Pharmacol 140 1051 PMID: 14530208
Dargan et al (2009) ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 121 PMID: 18789344
Potier et al (2010) Contribution of the d-Serine-Dependent Pathway to the Cellular Mechanisms Underlying Cognitive Aging. Front Aging Neurosci 2 1 PMID: 20552041
您是否知道使用了 Tocris L-689,560 的优秀论文？ 请告知我们.
L-689,560 的评论
目前没有该产品的评论。 Be the first to review L-689,560 and earn rewards!
Have you used L-689,560?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.